

Clinical Trials at CECORC

CECORC is currently participating in a number of clinical trials.

If you are interested in being part of a research clinical trial at RUHS Medical Center, please contact us at CECORC@ruhealth.org.

Clinical Trials active – 2020 - 2021

- Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity- SELECT (Novo Nordisk)
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People with Type 2 Diabetes – FOCUS (Novo Nordisk)
- The Effect of Tirzepatide versus Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes - SURPASS (Eli Lilly and Company)
- Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery (ANNEXA-S), enrolling early 2021 (Portola Pharmaceuticals)

Clinical Trials completed – 2019

- A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs – CONCLUDE (Novo Nordisk)
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis – ASCEND-ND (GlaxoSmithKline)
- A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of study medication in subjects with active ulcerative colitis (GlaxoSmithKline)